Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
about
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDEmergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsTargeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsThe Biology and Targeting of FLT3 in Pediatric Leukemia.The Future of Targeting FLT3 Activation in AML.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Identification of an orally available compound with potent and broad FLT3 inhibition activityA novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.Overcoming AC220 resistance of FLT3-ITD by SAR302503.Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsTTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Functional heterogeneity of genetically defined subclones in acute myeloid leukemiaNovel therapies for children with acute myeloid leukaemia.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.FLT3 inhibitors in AML: are we there yet?Targeting FLT3 to treat leukemia.Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.Novel approaches to pediatric leukemia treatment.Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.Mutated genes and driver pathways involved in myelodysplastic syndromes—a transcriptome sequencing based approach.Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants.An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemiaMidostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance.High expression of FLT3 is a risk factor in leukemia.Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
P2860
Q27852087-F42C5CE2-4F75-496E-8ED8-691E62930084Q27852520-98425F81-91FE-4F60-A0AA-F9646C92E918Q28289859-57514012-AD57-46A6-A1D8-DF06C7F572BFQ28539032-FD61A3A5-5A55-4035-BAB2-7A37E33C4D7BQ34229555-9D903A95-B9A6-485C-9D9B-CB276664B9C1Q34555386-06904D0E-39DC-49A5-9223-DEB8702476D2Q34993145-52135F14-6701-4340-AEF9-C2E6D44F498AQ35789739-0FFC51EB-BF1B-4F53-8761-90C21DACB302Q36366552-043AFE0C-A732-45BB-95FA-B9734C676AF7Q36408534-C313A576-D306-48F2-B12B-74BDC27EF849Q36693252-AB4C9966-C72F-42E9-A118-C078EE340B1FQ37148125-8BF3ACE0-0E20-4C92-9A41-EC08AB499EFAQ37429734-34CEA198-3AA8-4DE9-A7F1-99FDE20D14D9Q37623535-40D37EF4-AA44-4C58-ADFC-0FFC68B7B6A7Q37643136-79158455-FC80-458E-99AF-9246EFAAAB12Q37698123-A0EEACDD-1E1C-4F98-91EF-62B6225E3650Q38096798-0E9DE401-3163-4443-8BBE-76F34D031831Q38168893-380CE4A8-86DF-4C10-B07C-DA2EAA4B80A5Q38200564-29A94989-42C6-4354-89AD-6E50E51047AEQ38251339-1BDCFD1F-5AC1-4250-B2B0-CE805D4083E6Q38272140-7DD502E4-024B-44FF-B929-A1AE6999E0FAQ38500371-ECF4BD21-6AB1-44D8-B368-1524C5454E51Q38713196-49D8096D-2BF1-4933-8C30-B3343B487D56Q39016415-58FEC9F3-3F85-4193-BD45-9362A1A1E167Q40293334-600B74AB-095A-4D53-82FD-6C428F3044E0Q40902348-3241D09B-3723-4FE7-ABC3-9ECE27DBA3E7Q41760980-AA884EEB-650C-493D-AA3F-0143BF63BB04Q41819724-43C6CCFA-AF76-48EA-9FC7-17082071462DQ42376734-AA13E3AF-5A11-4053-B3A5-7B45F477E497Q44924469-7769DA83-76FE-491C-BD6A-04FB8385D771Q47283332-D2F0591D-DFC9-4E30-A030-2C8FB36492D4Q48273276-C160B16C-5018-4790-8563-D21901050AC3Q52571251-615D32DF-DD87-4179-848C-89E9ED9C01CDQ54114106-B00A6D9C-78E2-4ADE-9C00-C154F1D6E7F0Q54160284-2D49A8EB-0AE4-4201-8176-95D4A5039CC5Q54281304-5349A54E-9D36-431A-8A5D-5C6DC4F82E2E
P2860
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@en
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@nl
type
label
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@en
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@nl
prefLabel
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@en
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@nl
P2093
P2860
P356
P1433
P1476
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
@en
P2093
A B Williams
P2860
P2888
P356
10.1038/LEU.2012.191
P577
2012-07-13T00:00:00Z